ArticleFrontiers in immunology2025
Human Fcγ-receptors selectively respond to C-reactive protein isoforms.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluating the CRP Interactome: Insights into Possible Novel Roles in Cellular Signaling and Tumorigenicity.Current issues in molecular biology · 2025Review
- FcγRIIIA -activating antibodies in dengue virus infection reveals a distinct transient cross-reactive profile.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The pentameric C-reactive protein (pCRP), an acute-phase protein, binds to lysophosphatidylcholine (LPC) displayed on the surface of dying cells and microorganisms to activate the complement system and to opsonize immune cells via Fcγ-receptors (FcγRs). Members of the FcγR family are characterized by the recognition of the Fc part of IgG antibodies. Methods: We utilized a mouse thymoma BW5147 reporter cell panel stably expressing chimeric human FcγR-CD3ζ-chain receptors to define the molecular requirements for FcγR crosslinking by C-reactive protein (CRP). Results: Applying this approach, we show a robust activation of CD64/FcγRI and CD32a/FcγRIIa by immobilized CRP isoforms as well as triggering of inhibitory CD32b/FcγRIIb. Of note, activation of FcγRIIa was restricted to the 131R allelic variant but not observed with 131H. In contrast, FcγRIII isoforms CD16aF, CD16aV and CD16b were not activated by pCRP, although binding of CRP isoforms to FcγRIII was detectable. Activation of FcγRs by free pCRP in solution phase was considerably lower than with immobilized pCRP on hydrophilic plastic surfaces and readily abolished by IgG at serum level concentrations, whereas it was enhanced by the addition of streptococci. The types of FcγRs mainly responding to pCRP in solution phase (CD64/FcγRI and CD32aR/FcγRIIaR) clearly differed from FcγRs responding to soluble multimeric IgG complexes (i.e., CD16aV/FcγRIIIaV and CD32aH/FcγRIIaH). Compared to pCRP, monomeric CRP (mCRP) showed lower levels of activation in those selective FcγRs. FcγR activation was linked to recognition by conformation-dependent CRP antibodies. Unmasking of the mAb 9C9-defined neoepitope in pCRP* correlated with the triggering of FcγRs, indicating that pCRP* is the major FcγR-activating CRP conformation. Discussion: The assay provides a novel, scalable approach to determine the molecular properties of CRP as a physiological ligand of FcγR-mediated bioactivities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.